natgillin/translations-raw huggingface dataset:
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 60 actuations 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 60 sprožitev
No differences were observed when comparing Riarify and the extemporary triple combination made of fluticasone and vilanterol fixed combination plus tiotropium. 
V primerjavi zdravila Riarify in trojne kombinacije, sestavljene iz fiksne kombinacije flutikazona in vilanterola plus tiotropija ni bilo opaznih razlik.
The active substances are: beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium. 
Učinkovine so: beklometazondipropionat, formoterolijev fumarat dihidrat in glikopironij.
• depression 
• utrujenost
No differences were observed when comparing Riarify with the extemporary triple combination made of beclometasone dipropionate and formoterol fixed combination plus tiotropium (moderate/severe exacerbation rate: 0.46 versus 0.45 events per patient/year). 
V primerjavi zdravila Riarify s trojno kombinacijo, ki je bila sestavljena iz fiksne kombinacije beklometazondipropionata in formoterola plus tiotropija, niso opazili razlik (razmerje zmernih/hudih poslabšanj: 0,46 v primerjavi z 0,45 dogodka na bolnika/leto).
• inflammation of the ear 
• vnetje ušesa
• a container providing 120 puffs 
• vsebnik, ki zagotavlja 120 vdihov
Riarify is used as a maintenance treatment for your COPD. 
Zdravilo Riarify se uporablja za vzdrževalno zdravljenje KOPB.
1 pressurised container of 60 actuations. 
1 tlačni vsebnik s 60 sprožitvami
1 pressurised container of 120 actuations. 
1 tlačni vsebnik s 120 sprožitvami
Compared with a fixed combination of indacaterol and glycopyrronium, Riarify improved average pre-dose FEV1 over the 52-week treatment period by 22 mL (p=0.018). 
V primerjavi s fiksno kombinacijo indakaterola in glikopironija je zdravilo Riarify izboljšalo povprečni FEV1 pred odmerkom po 52-tedenskem zdravljenju za 22 ml (p = 0,018).
2-hour post-dose FEV1 
FEV1 2 uri po odmerku
Beclometasone dipropionate is a pro-drug with weak glucocorticoid receptor binding affinity that is hydrolysed via esterase enzymes to an active metabolite beclometasone 17-monopropionate which has a more potent topical anti-inflammatory activity compared with the pro-drug beclometasone dipropionate. 
Beklometazondipropionat je predzdravilo s šibko afiniteto za vezavo na glukokortikoidne receptorje, ki se hidrolizira preko encimov esteraze v aktivni presnovek beklometazon 17-monopropionat, ki ima močnejšo lokalno protivnetno aktivnost v primerjavi s predzdravilom beklometazondipropionatom.
• a container providing 180 puffs. 
• vsebnik, ki zagotavlja 180 vdihov
• Disulfiram, a medicine used in the treatment of people with alcoholism (drinking problems) or metronidazole, an antibiotic to treat infection in your body can cause side effects (e.g. feeling sick, being sick, stomach pain) due to the small amount of alcohol in Riarify. 
• disulfiram, zdravilom, ki se uporablja za zdravljenje ljudi z alkoholizmom ali metrodinazolom, antibiotikom za zdravljenje okužb v telesu lahko zaradi majhne količine alkohola v zdravilu
Patients with severe renal impairment 
Bolniki s hudo okvaro ledvic
- when using the container providing 60 puffs 
- če uporabljate vsebnik, ki zagotavlja 60 vdihov
Blood pressure increased1, blood pressure decreased1 
občasni zvišanje krvnega tlaka1, zmanjšanje krvnega tlaka1
Possible systemic effects include: Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation, decrease in bone mineral density, cataract, glaucoma and, more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children). 
zmanjšanje mineralne gostote kosti, katarakto, glavkom in redkeje vrsto psiholoških ali vedenjskih učinkov, vključno s psihomotorično hiperaktivnostjo, motnjami spanja, anksioznostjo, depresijo ali agresijo (zlasti pri otrocih).
Remove the protective cap from the mouthpiece 
Odstranite zaščitni pokrovček z ustnika.
After repeated inhalation of twice daily doses ranging from 12.5 to 50 micrograms via pressurised metered dose inhaler in COPD patients, glycopyrronium showed linear pharmacokinetics with little systemic accumulation at steady state (median accumulation ratio 
50 mikrogramov skozi inhalator pod tlakom z določenim odmerkom pri bolnikih s KOPB je glikopironij pokazal linearno farmakokinetiko z majhno sistemsko akumulacijo v stanju dinamičnega ravnovesja (mediana razmerja akumulacija 2,2-2,5).
Beclometasone dipropionate/beclometasone-17-monopropionate was considered responsible for reproductive toxicity effects in rats such as reduction of the conception rate, fertility index, early embryonic development parameters (implantation loss), delay in ossification and increased incidence of visceral variations; while tocolytic and anti-muscarinic effects, attributed to the beta2-adrenergic activity of formoterol and the anti-muscarinic activity of glycopyrronium, affected pregnant rats in the late phase of gestation and/or early phase of lactation, leading to loss of pups. 
Smatra se, da je beklometazondipropionat/beklometazon 17-monopropionat odgovoren za vpliv na sposobnost razmnoževanja pri podganah, na primer zmanjšanje stopnje koncepcije, indeksa plodnosti, parametrov zgodnjega embrionalnega razvoja (izguba implantacije), zapoznela okostenitev in povečana incidenca visceralnih sprememb; medtem ko so tokolitični in antimuskarinski učinki,
60 actuation pressurised container: 
Tlačni vsebnik s 60 sprožitvami:
Ear and labyrinth disorders Otosalpingitis1 
Ušesne bolezni, vključno z motnjami labirinta otosalpingitis1
Formoterol: hypokalaemia, hyperglycaemia, tremor, palpitations, muscle spasms, electrocardiogram QT prolonged, blood pressure increased, blood pressure decreased, atrial fibrillation, tachycardia, tachyarrhythmia, angina pectoris (stable and unstable), ventricular extrasystoles, nodal rhythm. 
QT na elektrokardiogramu, zvišanje krvnega tlaka, znižanje krvnega tlaka, atrijska fibrilacija, tahikardija, tahiaritmija, angina pektoris (stabilna in nestabilna), ventrikularne ekstrasistole, nodalni ritem;
- when using the container providing 120 puffs 
- če uporabljate vsebnik, ki zagotavlja 120 vdihov
Each time you press the pressurised container, a puff of medicine is released and the counter will count down by one. 
Vsakič ko pritisnete na tlačni vsebnik, se sprosti odmerek zdravila, števec pa se pomakne za eno navzdol.
Simulations performed with a pharmacokinetic model showed that even when covariates had extreme values (body weight less than 40 kg and concomitant glomerular filtration rate below 27 mL/min/1.73 m²), exposure to Riarify active substances remains in approximately a 2.5-fold range compared to the exposure in a typical patient with median covariate values. 
(telesna masa manj kot 40 kg in sočasno stopnja glomerularne filtracije pod 27 ml/min/1,73 m²) izpostavljenost učinkovinam v zdravilu Riarify ostala v razponu približno 2,5-kratnika v primerjavi z izpostavljenostjo običajnega bolnika z mediano vrednostjo sospremenljivk.
TRIBUTE was a 52-week activecontrolled study comparing Riarify with a fixed combination of indacaterol/glycopyrronium 85/43 micrograms inhalation powder, hard capsule, one inhalation once daily (1,532 randomised patients). 
52-tedenska študija, nadzorovana z učinkovino, v kateri so primerjali zdravilo Riarify s fiksno kombinacijo indakaterola/glikopironija 85/43 mikrogramov prašek za inhaliranje, trda kapsula, ena inhalacija enkrat na dan (1.532 randomiziranih bolnikov).
• runny or stuffy nose and sneezing 
• srbeč nos, izcedek iz nosu ali zamašen nos;
Compared with a fixed combination of beclometasone dipropionate and formoterol, Riarify significantly improved 2-hour post dose FEV1 by 117 mL after 26 weeks of treatment and by 103 mL after 52 weeks of treatment (p < 0.001). 
V primerjavi s fiksno kombinacijo beklometazondipropionata in formoterola je zdravilo Riarify značilno izboljšalo FEV1 2 uri po odmerku za 117 ml po 26-tedenskem zdravljenju in za 103 ml po 52-tedenskem zdravljenju (p < 0,001).
Chiesi Hellas AEBE Τηλ: + 30 210 6179763 
Τηλ: +30 210 6179763
Beclometasone dipropionate given by inhalation at recommended doses has a glucocorticoid antiinflammatory action within the lungs. 
Beklometazondipropionat V priporočenih odmerkih inhalirani beklometazondipropionat deluje v pljučih glukokortikoidno protivnetno.
Take care not to drop the inhaler as this may cause the counter to count down. 
Pazite, da vam inhalator ne pade iz rok, ker to lahko povzroči odštevanje števca.
The other ingredients are: ethanol anhydrous, hydrochloric acid, propellant: norflurane. 
Druge sestavine so: brezvodni etanol, klorovodikova kislina, potisni plin norfluran.
Systemic exposure (AUC0-t) to beclometasone dipropionate, to its metabolite beclometasone 17-monopropionate and to formoterol was not affected by mild to severe renal impairment. 
Blaga do huda okvara ledvic ni vplivala na sistemsko izpostavljenost (AUC0-t) beklometazondipropionata, njegovemu presnovku beklometazon 17-monopropionatu in formoterolu.
The maximum plasma concentration and systemic exposure of beclometasone dipropionate main active metabolite (beclometasone 17-monopropionate) and formoterol were similar after administration of the fixed or extemporary combination. 
Največja koncentracija v plazmi in sistemska izpostavljenost glavnega presnovka beklometazondipropionata (beklometazon 17-monopropionat) in formoterola sta bili podobni po dajanju fiksne kombinacije ali trojne kombinacije, ki je bila sestavljena iz fiksne kombinacije beklometazondipropionata in formoterola plus glikopironija.
- when using the container providing 180 puffs 
- če uporabljate vsebnik, ki zagotavlja 180 vdihov
Compared with a fixed combination of beclometasone dipropionate and formoterol, Riarify improved pre-dose FEV1 by 81 mL after 26 weeks of treatment and by 63 mL after 52 weeks of treatment. 
V primerjavi s fiksno kombinacijo beklometazondipropionata in formoterola je zdravilo Riarify izboljšalo FEV1 pred odmerkom za 81 ml po 26-tedenskem zdravljenju in za 63 ml po 52-tedenskem zdravljenju.
If you want to do this, talk to your doctor. 
Če želite prenehati uporabljati zdravilo, se posvetujte z zdravnikom.
Multipack: 360 actuations (3 pressurised containers of 120 actuations each). 
Skupno pakiranje: 240 sprožitev (2 tlačna vsebnika s po 120 sprožitvami) Skupno pakiranje: 360 sprožitev (3 tlačni vsebniki s po 120 sprožitvami) 1 tlačni vsebnik s 180 sprožitvami
Riarify is a pressurised inhalation, solution. 
Zdravilo Riarify je inhalacijska raztopina pod tlakom.
120 and 180 actuation pressurised container: 
Tlačni vsebnik s 120 in 180 sprožitvami:
Patients with severe hepatic impairment 
Bolniki s hudo okvaro jeter
Remove the protective cap from the mouthpiece and check that the mouthpiece is clean and free from dust and dirt. 
Z ustnika odstranite zaščitni pokrovček in preverite, če je ustnik čist, da ni zaprašen ali umazan in da je brez kakšnih tujih delcev.
Immediate hypersensitivity reactions have been reported after administration of Riarify. 
Preobčutljivost Po jemanju zdravila Riarify so poročali o takojšnjih preobčutljivostnih reakcijah.
Related to Riarify 
V povezavi z zdravilom Riarify
C-reactive protein increased1, platelet count increased1, free fatty acids increased1, blood insulin increased1, blood ketone body increased1, cortisol decreased1 
Preiskave zvečanje ravni C-reaktivnega proteina1, počano število trombocitov1, zvečanje vrednosti prostih maščobnih kislin1, zvečanje ravni insulina v krvi1, zvečanje vrednosti ketonskih teles v krvi1, zmanjšanje ravni kortizola1
• increase in the level of some constituents of your blood: glucose, C-reactive protein, 
• zvišanje ravni nekaterih sestavin v krvi: glukoze, C-reaktivnega proteina, števila trombocitov, inzulina, prostih maščobnih kislin ali ketonov.
Pneumonia (in COPD patients), pharyngitis, oral candidiasis, urinary tract infection1, nasopharyngitis1 
Infekcijske in parazitske bolezni pljučnica (pri bolnikih s KOPB), faringitis, oralna kandidiaza, okužba sečil1, nazofaringitis1
After dispensing, the medicinal product may be stored for a maximum of 2 months at a temperature up to 25°C. 
Po izdaji zdravila se lahko zdravilo shranjuje največ 2 meseca pri temperaturi do 25 °C.
After dispensing, the medicinal product may be stored for a maximum of 4 months at a temperature up to 25°C. 
Po izdaji zdravila se lahko zdravilo shranjuje največ 4 mesece pri temperaturi do 25 °C.
• weakness 
• slabost;
Compared with a fixed combination of indacaterol and glycopyrronium, Riarify reduced the rate of moderate/severe exacerbations over 52 weeks by 15% (rate: 0.50 versus 0.59 events per patient/year; p = 0.043). 
V primerjavi s fiksno kombinacijo indakaterola in glikopironija je zdravilo Riarify v 52 tednih zmanjšalo stopnjo zmernih/hudih poslabšanj za 15 % (razmerje: 0,50 v primerjavi z 0,59 dogodka na bolnika/leto; p = 0,043).
Blood and lymphatic system disorders 
Bolezni krvi in limfatičnega sistema granulocitopenija1
Hold the inhaler upright with the mouthpiece at the bottom and place the mouthpiece between your teeth without biting it. Then place your lips around the mouthpiece, with the tongue flat under it. 
Inhalator držite pokončno, z ustnikom spodaj, nato pa vstavite ustnik med zobe, vendar ga ne smete ugrizniti.
Pressurised inhalation, solution. 
inhalacijska raztopina pod tlakom
Pharmacotherapeutic group: Drugs for obstructive airway diseases, adrenergics in combination with anticholinergics incl. 
Farmakoterapevtska skupina: druga sistemska zdravila za obstruktivne pljučne bolezni, adrenergiki v kombinaciji z antiholinergiki, vključno s kortikosteroidi v trojnih kombinacijah, oznaka ATC: R03AL09.
Potentially serious hypokalaemia may result from beta2-agonist therapy. 
Zdravljenje z agonistom adrenergičnih receptorjev beta2 lahko povzroči potencialno resno hipokaliemijo.
Muscle spasms, myalgia, pain in extremity1, musculoskeletal chest pain1 
Bolezni mišično-skeletnega sistema in vezivnega tkiva mišični spazem, mialgija, bolečine v okončinah1, mišično-skeletna bolečina v prsnem košu1
Dysuria, urinary retention, nephritis1 
Bolezni sečil disurija, retencija urina, nefritis1
• urinary tract infection. 
retencija urina, okužba sečil.
Each delivered dose contains 87 micrograms of beclometasone dipropionate, 5 micrograms of formoterol fumarate dihydrate and 9 micrograms of glycopyrronium. 
En dostavljeni odmerek vsebuje 87 mikrogramov beklometazondipropionata, 5 mikrogramov formoterolijevega fumarata dihidrata in 9 mikrogramov glikopironija.
Glycopyrronium: glaucoma, atrial fibrillation, tachycardia, palpitations, dry mouth, dental caries, dysuria, urinary retention, urinary tract infection. 
glikopironijem: glavkom, atrijska fibrilacija, tahikardija, palpitacije, suha usta, zobni karies, disurija,
Bone density decreased1 
redki zmanjšanje kostne gostote1
• inflammation of the sinuses 
• vnetje sinusov;
Hold your inhaler upright with the mouthpiece at the bottom Direct the mouthpiece away from yourself and firmly press the pressurised container to release one puff 
Usmerite ustnik proč od sebe in trdno pritisnite tlačni vsebnik navzdol, da sprostite en odmerek.
If you are testing your inhaler for the first time, the counter should read: 
Če inhalator preverjate prvič, mora števec odmerkov kazati 60.
Diarrhoea1, dry mouth, dysphagia1, nausea, dyspepsia1, burning sensation of the lips1, dental caries1, (aphthous) stomatitis 
Bolezni prebavil driska1, suha usta, disfagija1, navzea1, dispepsija1, skeleč občutek na ustnicah1, zobni karies1, (aftozni) stomatitis občasni Bolezni kože in podkožja izpuščaj1, urtikarija1, pruritus, hiperhidroza1
Compared with a fixed combination of beclometasone dipropionate and formoterol, Riarify reduced the rate of moderate/severe exacerbations over 52 weeks by 23% (rate: 0.41 versus 0.53 events per patient/year; p = 0.005). 
V primerjavi s fiksno kombinacijo beklometazondipropionata in formoterola je zdravilo Riarify v 52 tednih zmanjšalo stopnjo zmernih/hudih poslabšanj za 23 % (razmerje: 0,41 v primerjavi z 0,53 dogodka na bolnika/leto; p = 0,005).
Pre-dose FEV1 
FEV1 pred odmerkom
Just after starting to breathe in, press down firmly on the top of the pressurised container to release one puff. 
Takoj potem, ko začnete vdihavati, čvrsto pritisnite na zgornji del tlačnega vsebnika,
Compared with tiotropium, Riarify reduced the rate of moderate/severe exacerbations over 52 weeks by 20% (rate: 0.46 versus 0.57 events per patient/year; p = 0.003). 
V primerjavi s tiotropijem je zdravilo Riarify v 52 tednih zmanjšalo stopnjo zmernih/hudih poslabšanj za 20 % (razmerje: 0,46 v primerjavi z 0,57 dogodka na bolnika/leto; p = 0,003).
TRISTAR was a 26-week active-controlled open label study comparing Riarify with an extemporary combination made of a fixed combination of fluticasone/vilanterol 92/22 micrograms inhalation powder, one inhalation once daily plus tiotropium 18 micrograms inhalation powder, hard capsule, one inhalation once daily (1,157 randomised patients). 
Riarify s kombinacijo, sestavljeno iz fiksne kombinacije flutikazona/vilanterola 92/22 mikrogramov prašek za inhaliranje, ena inhalacija enkrat na dan plus tiotropij 18 mikrogramov prašek za inhaliranje, trda kapsula, ena inhalacija enkrat na dan (1.157 randomiziranih bolnikov).
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS ALUMINIUM CONTAINER 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
Patients who find it difficult to synchronise aerosol actuation with inspiration of breath may use the AeroChamber Plus spacer device, properly cleaned as described in the relevant leaflet. 
Bolniki, ki s težavo uskladijo sprožitev aerosola z vdihavanjem, lahko uporabljajo nastavek
Excipients: anhydrous ethanol, hydrochloric acid; propellant: norflurane. 
Pomožne snovi: brezvodni etanol, klorovodikova kislina, potisni plin norfluran.
Following inhalation, formoterol is absorbed from both the lung and the gastrointestinal tract. 
Absorpcija in porazdelitev Po inhalaciji se formoterol absorbira iz pljuč in prebavil.
Riarify 87/5/9 micrograms pressurised inhalation, solution beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium 
Riarify 87/5/9 mikrogramov inhalacijska raztopina pod tlakom beklometazondipropionat/formoterolijev fumarat dihidrat/glikopironij
• fungal infections of the mouth. 
• glivične okužbe (ust).
The study compared data obtained after treatment with a single dose of Riarify (4 inhalations of 100/6/25 micrograms, a non-marketed formulation containing twice the approved strength of glycopyrronium) or a single dose of the extemporary combination of beclometasone dipropionate/formoterol (4 inhalations of 100/6 micrograms) plus glycopyrronium (4 inhalations of 25 micrograms). 
100/6/25 mikrogramov, s formulacijo, ki je ni na trgu n ki vsebuje dvakratno odobreno jakost glikopironija) ali enkratnim odmerkom trojne kombinacije, ki je bila sestavljena iz fiksne kombinacije beklometazondipropionata in formoterola 100/6 mikrogramov (4 inhalacije po 100/6 mikrogramov)
Riarify significantly improved dyspnoea (measured as the Transition Dyspnoea Index - TDI - focal score) after 26 weeks of treatment compared with baseline (by 1.71 units; p < 0.001), but the adjusted mean difference versus a fixed combination of beclometasone dipropionate and formoterol was not statistically significant (0.21 units; p = 0.160). 
p < 0,001), vendar prilagojena srednja razlika v primerjavi s fiksno kombinacijo beklometazondipropionata in formoterola ni bila statistično značilna (0,21 enot; p = 0,160).
Beclometasone dipropionate: pneumonia, oral fungal infections, lower respiratory tract infection fungal, dysphonia, throat irritation, hyperglycaemia, psychiatric disorders, cortisol decreased, blurred vision. 
Med neželenimi učinki, ki so jih opazili, so naslednji običajno povezani z: beklometazondipropionatom: pljučnica, oralna glivična okužba, glivična okužba spodnjih dihal, disfonija, draženje žrela, hiperglikemija, psihiatrične motnje, zmanjšanje ravni kortizola, zamegljen vid;
After a glycopyrronium single i.v. 
Po enkratni i.v.
The renal excretion of beclometasone dipropionate and its metabolites is negligible. 
Izločanje beklometazondipropionata in njegovih presnovkov skozi ledvice je zanemarljivo.
Each delivered dose (the dose leaving the mouthpiece) contains 87 micrograms of beclometasone dipropionate, 5 micrograms of formoterol fumarate dihydrate and 9 micrograms of glycopyrronium (as 11 micrograms glycopyrronium bromide). 
En dostavljen odmerek (odmerek, ki zapusti ustnik) vsebuje 87 mikrogramov beklometazondipropionata, 5 mikrogramov formoterolijevega fumarata dihidrata in 9 mikrogramov glikopironija (v obliki 11 mikrogramov glikopironijevega bromida).
• diarrhoea 
• omrtvelost
Package leaflet: Information for the user Riarify 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium 
Navodilo za uporabo Riarify 87 mikrogramov/5 mikrogramov/9 mikrogramov inhalacijska raztopina pod tlakom beklometazondipropionat/formoterolijev fumarat dihidrat/glikopironij
Riarify should be used with caution in patients with cardiac arrhythmias, especially third degree atrioventricular block and tachyarrhythmias (accelerated and/or irregular heart beat), idiopathic subvalvular aortic stenosis, hypertrophic obstructive cardiomyopathy, severe heart disease (particularly acute myocardial infarction, ischaemic heart disease, congestive heart failure), occlusive vascular diseases (particularly arteriosclerosis), arterial hypertension and aneurysm. 
idiopatsko subvalvularno aortno stenozo, hipertrofično obstruktivno kardiomiopatijo, hudo boleznijo srca (zlasti akutni miokardni infarkt, ishemična bolezen srca, kongestivno srčno popuščanje),
Each metered dose (the dose leaving the valve) contains 100 micrograms of beclometasone dipropionate, 6 micrograms of formoterol fumarate dihydrate and 10 micrograms of glycopyrronium. 
En odmerjen odmerek (odmerek, ki zapusti ventil) vsebuje 100 mikrogramov beklometazondipropionata, 6 mikrogramov formoterolijevega fumarata dihidrata in 10 mikrogramov glikopironija.
Ethanol anhydrous Hydrochloric acid Norflurane (propellant) 
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi brezvodni etanol klorovodikova kislina norfluran (potisni plin)
The (R,R)- and (S,S)-enantiomers represented about 40% and 60% of unchanged active substance excreted in the urine, respectively. 
Enantiomeri (R,R) in (S,S) predstavljata približno
Riarify 87/5/9 micrograms pressurised inhalation beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium Inhalation use 
Riarify 87/5/9 mikrogramov inhalacijska raztopina pod tlakom beklometazondipropionat/formoterolijev fumarat dihidrat/glikopironij za inhaliranje
Wipe inside and outside of the mouthpiece and the inhaler with a clean, dry cloth or tissue. 
Odstranite zaščitni pokrovček z ustnika tako, da jo snamete z inhalatorja Zunanjost in notranjost ustnika ter inhalator obrišite s čisto suho krpo ali papirnatim robčkom Pokrovček namestite nazaj na ustnik.
If you get any side effects talk to your doctor or pharmacist. 
Če opazite katerega koli izmed neželenih učinkov, se posvetujte z zdravnikom ali farmacevtom.
Each metered dose (the dose leaving the valve) contains 100 micrograms of beclometasone dipropionate, 6 micrograms of formoterol fumarate dihydrate and 10 micrograms of glycopyrronium (as 12.5 micrograms of glycopyrronium bromide). 
En odmerjen odmerek (odmerek, ki zapusti ventil) vsebuje 100 mikrogramov beklometazondipropionata, 6 mikrogramov formoterolijevega fumarata dihidrata in 10 mikrogramov glikopironija (v obliki 12,5 mikrograma glikopironijevega bromida).
Priming the inhaler 
Priprava inhalatorja
Tremor, dizziness, dysgeusia1, hypoaesthesia1 
Bolezni živčevja glavobol pogosti tremor, omotica, disgevzija1, hipoestezija1
• fungal infections of the chest 
• glivične okužbe žrela ali požiralnika;
• skin rash, hives, skin itching 
• kožni izpuščaj, koprivnica, srbenje kože;
Testing your inhaler 
Preverjanje inhalatorja
• pain in the back of the mouth and throat 
• bolečina v zadnjem delu ust in žrelu; • vnetje in rdečina žrela;